DK1011673T3 - Hidtil ukendt metode til behandling af nidom - Google Patents

Hidtil ukendt metode til behandling af nidom

Info

Publication number
DK1011673T3
DK1011673T3 DK98929228T DK98929228T DK1011673T3 DK 1011673 T3 DK1011673 T3 DK 1011673T3 DK 98929228 T DK98929228 T DK 98929228T DK 98929228 T DK98929228 T DK 98929228T DK 1011673 T3 DK1011673 T3 DK 1011673T3
Authority
DK
Denmark
Prior art keywords
nidoma
treating
hitherto unknown
unknown method
metformin
Prior art date
Application number
DK98929228T
Other languages
Danish (da)
English (en)
Inventor
Lisbeth Tofte Hemmingsen
Peter Giortz Mueller
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26064473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1011673(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK1011673T3 publication Critical patent/DK1011673T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98929228T 1997-06-13 1998-06-12 Hidtil ukendt metode til behandling af nidom DK1011673T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK69497 1997-06-13
US6336897P 1997-10-29 1997-10-29
PCT/DK1998/000248 WO1998056378A1 (en) 1997-06-13 1998-06-12 Novel niddm regimen

Publications (1)

Publication Number Publication Date
DK1011673T3 true DK1011673T3 (da) 2001-07-09

Family

ID=26064473

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98929228T DK1011673T3 (da) 1997-06-13 1998-06-12 Hidtil ukendt metode til behandling af nidom

Country Status (13)

Country Link
US (1) US6677358B1 (pt)
EP (2) EP1097710B1 (pt)
JP (2) JP2002500677A (pt)
AT (1) ATE201139T1 (pt)
AU (1) AU7906898A (pt)
DE (1) DE69800806T2 (pt)
DK (1) DK1011673T3 (pt)
ES (1) ES2159184T3 (pt)
GR (1) GR3036078T3 (pt)
HK (1) HK1030872A1 (pt)
PT (1) PT1011673E (pt)
WO (1) WO1998056378A1 (pt)
ZA (1) ZA985126B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
JP4175662B2 (ja) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ．ヴイ． 電気的筋肉制御装置
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
SK8902002A3 (en) 1999-12-23 2002-11-06 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
PL356300A1 (en) * 1999-12-28 2004-06-28 Ajinomoto Co, Inc. Oral preparations for diabetes
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
EP1255718A1 (en) * 2000-02-01 2002-11-13 Stevia APS A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
AU2003231517A1 (en) * 2002-04-26 2003-11-10 Ajinomoto Co., Inc. Preventive/remedy for diabetes
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
EP1898991B1 (en) 2005-05-04 2016-06-29 Impulse Dynamics NV Protein activity modification
EP2026787B1 (en) * 2006-05-13 2013-12-25 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
EP2073796A1 (en) * 2006-09-29 2009-07-01 Novo Nordisk A/S Pharmaceutical formulation comprising metformin and repaglinide
CN101756971B (zh) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 一种盐酸二甲双胍瑞格列奈的口服固体药物组合物
WO2011092710A2 (en) 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
AU660930B2 (en) * 1991-06-21 1995-07-13 Novo Nordisk A/S (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid

Also Published As

Publication number Publication date
EP1011673B1 (en) 2001-05-16
DE69800806D1 (de) 2001-06-21
ZA985126B (en) 1998-12-14
ATE201139T1 (de) 2001-06-15
EP1097710A3 (en) 2002-05-29
GR3036078T3 (en) 2001-09-28
EP1097710A2 (en) 2001-05-09
HK1030872A1 (en) 2001-05-25
JP2002500677A (ja) 2002-01-08
EP1011673A1 (en) 2000-06-28
JP2004155791A (ja) 2004-06-03
DE69800806T2 (de) 2001-09-13
US6677358B1 (en) 2004-01-13
PT1011673E (pt) 2001-11-30
AU7906898A (en) 1998-12-30
WO1998056378A1 (en) 1998-12-17
ES2159184T3 (es) 2001-09-16
EP1097710B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
DK1011673T3 (da) Hidtil ukendt metode til behandling af nidom
DE59005543D1 (de) Walze zur druckbehandlung von warenbahnen.
TR199902124T2 (xx) �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller.
NO911694L (no) Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav.
FR2712286B1 (fr) Nouveaux N-mercaptoalkyl alcanediamines et leur utilisation.
DE3765443D1 (de) Anordnung zur ansteuerung von mehreren im tandembetrieb arbeitenden nichtmechanischen druckgeraeten.
NO842237L (no) Fleksibel, hurtigbehandlende fotopolymeriserbar sammensetning.
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
DE69525279T2 (de) Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder
DK71387A (da) Terapeutisk middel til behandling af psoriasis
DE69205466D1 (de) Mittel zur Kontrolle von Hautfalten, die die Arg-Ser-Arg-Lys-Sequenzen enthalten.
NO901535L (no) Molekylaersikter og anvendelse derav som oksydasjonskatalysator.
NO972449D0 (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on 1,1 dioksidderivater og preparater og fremgangsmåte for anvendelse derav
DE59106547D1 (de) Mittel zur oxidativen färbung von haaren und neue 5-halogen-2,4-diaminoalkylbenzole.
DE59204515D1 (de) Maschine zum behandeln von teig.
DE3679927D1 (de) Mittel zum behandeln von textilien.
DE69508712T2 (de) Verfahren zum Unschädlichmachen von Herbiziden im Getreide unter Verwendung von 5-Aryloxy-1,2-(disubstituierten) Benzolverbindungen
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
DE3781865D1 (de) Klonierung von dns, welche einen menschlichen gip-vorlaeufer kodiert und expressionsverfahren des vorlaeufers.
WO1995024896A3 (en) Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne
DE68906775D1 (de) Mittel zum schuetzen, ernaehren und behandeln der haut.
NO985558L (no) Ny forbedret formulering for behandling av tromboembolisme
BR8904924A (pt) Composicao de tratamento de couro,sua utilizacao,processo para tratamento de couros,bem como couro assim tratado
ATE49964T1 (de) Benzodioxepane, verfahren zur herstellung und verwendung als heilmittel.